Incidence of Bleeding, Thrombosis and Transfusion Requirements in ICU Patients With COVID-19 Supported With Veno-venous Extracorporeal Membrane Oxygenation

Sponsor
Rigshospitalet, Denmark
Study ID
NCT07352072
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Bleeding
  • COVID-19
  • Thrombosis
  • Transfusion Adverse Reaction
  • VV ECMO

Eligibility Criteria

Sex
ALL
Age
N/A - N/A
Healthy Volunteers
Not accepted

Study Details

The investigators aim to assess the risk of bleeding and thrombo-embolic complications as well as benefit and harm of blood product transfusion and anticoagulation therapy in adult ICU patients with COVID-19 supported with V-V ECMO

Key Dates

First listed
Jan 20, 2026
Start date
Jan 31, 2026
Status verified
Jan 2026
Primary completion
Jun 30, 2026
Completion
Dec 31, 2026

Study Design

Enrollment
50 participants (estimated)

Arms

  • Arm: Patients with COVID-19 induced ARDS supported with VV ECMO in eastern Denmark
    a single-center retrospective cohort study of all adult ICU patients with COVID-19 infection supported with veno-venous extracorporeal membrane oxygenation admitted to the cardio-thoracic intensive care unit at Copenhagen University Hospital, Rigshospitalet.

Primary Outcome Measure

Bleeding events [ Time Frame: 90 days ]

Central Contacts

Find similar trials

Nationwide
COVID-19 / long COVID trialsInfectious disease trials

Related Studies